JP2008279238A - Regeneration treatment of arthropathy (heberden's nodositas), rheumatism, severe collagenosis marginal disease patient by gene therapy - Google Patents
Regeneration treatment of arthropathy (heberden's nodositas), rheumatism, severe collagenosis marginal disease patient by gene therapy Download PDFInfo
- Publication number
- JP2008279238A JP2008279238A JP2007159514A JP2007159514A JP2008279238A JP 2008279238 A JP2008279238 A JP 2008279238A JP 2007159514 A JP2007159514 A JP 2007159514A JP 2007159514 A JP2007159514 A JP 2007159514A JP 2008279238 A JP2008279238 A JP 2008279238A
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- arthropathy
- rheumatism
- disease
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Description
再生医療とは機能不全に陥った臓器や何らかの原因で欠損した組織の機能を再生したり、臓器・組織の再生を促す、生理活性注射をして、人体内で自力での再生を助ける治療法です。
再生医療の解釈を広げるとエリスロポエチンの注射による貧血の治療や顆粒状コロニー刺激因子による白血球減少の治療も含まれます。Regenerative medicine is a treatment method that regenerates the function of organs that have become dysfunctional or tissue that has been lost due to any cause, or promotes the regeneration of organs or tissues, and performs bioactive injection to help the body regenerate itself. is.
Broadening the interpretation of regenerative medicine includes the treatment of anemia with erythropoietin injection and the treatment of leukopenia with granular colony stimulating factor.
1995年、ADA欠損症・何種類かのがんに対して遺伝子治療が実施されております。In 1995, gene therapy was implemented for ADA deficiency and several types of cancer.
遺伝子治療による再生治療は整形外科分野ではまだ実施されていない様です。
広範囲熱湯で失なわれた皮膚部分を治すため、残った皮膚を培養して、シート状に増やした「再生皮膚」を用いる治療があります。Regenerative treatment with gene therapy has not yet been implemented in the orthopedic field.
In order to cure the skin that has been lost with a wide range of hot water, there is a treatment that uses "regenerated skin" that has been cultivated and increased to form a sheet.
角膜潰瘍で失った角膜を治すため、口内の粘膜細胞などを培養して、増やして「再生上皮」で潰瘍部分を張り替える治療などがあります。
21世紀の人類の進歩における重要な柱と位置付けられている。
バイオ技術、バイオ関連企業の動向、ゲノムや遺伝子診断、ゲノム創薬など、バイオテクノロジーに関する見出しが目立っている。病気の原因は遺伝子で説明されようとしている。
糖尿病・高脂症高血圧などの成人病・又は生活習慣病は家系内に多く発生している場合に同じ病気にかかる可能性が高く、原因として、病気の遺伝的素因の可能性が指摘されて来た。
心臓病・脳梗塞・感染症・悪性腫瘍(癌)とさまざまです。
今日、これらの多くの病気の原因は、多かれ少なかれ、遺伝子が関わっていると考えられている。
遺伝子解析技術の進歩により、さまざまな病気発症のしくみや個人差が遺伝子レベルで解明されるようになりました。
遺伝子検査はこれらの病気の原因遺伝子を検出することによって、病気の早期診断と適切な治療薬の選拓により、有効な治療、さらには重症化を防ぐことができるようになります。
これらの取り組みは、2003年にヒト染色体の全遺伝配列情報(ゲノム)の解読が完了したため、加速しております。
遺伝子検査によって得られる情報には限界があり、使い方を誤ると、高額な検査費用を浪費するばかりか、有害な情報を提供してしまう危険もあります。
遺伝子検査に関する適切な知識と理解が必要です。It is positioned as an important pillar in human progress in the 21st century.
Biotechnology, biotechnology-related trends, genome and gene diagnosis, genome drug discovery, and other biotechnology headings are prominent. The cause of the disease is being explained by genes.
Adult diseases such as diabetes, hyperlipidemia, and hypertension, or lifestyle-related diseases are more likely to occur in the family if they occur frequently in the family, and the cause may be a genetic predisposition to the disease. I came.
There are various cases such as heart disease, cerebral infarction, infectious disease, malignant tumor (cancer).
Today, the causes of many of these diseases are more or less thought to be related to genes.
Advances in gene analysis technology have made it possible to elucidate the mechanisms of various diseases and individual differences at the genetic level.
Genetic testing detects the causative genes of these diseases, so that early treatment of the diseases and the selection of appropriate treatments can help prevent effective treatment and even worsening of the disease.
These efforts are accelerating because the complete genetic sequence information (genome) of the human chromosome was completed in 2003.
There is a limit to the information that can be obtained by genetic testing, and misuse can not only waste expensive testing costs but also provide harmful information.
Appropriate knowledge and understanding of genetic testing is required.
マウスによる遺伝子による検査をたくさん実施し、各疾患に対しての知識を得る事が必要と思われます。
関節症(ヘバーデン結節症)、リウマチ、膠原病数縁疾患は遺伝病ですから、遺伝病として扱い、それに対しての再生治療を実施した方が良いと考えます。It would be necessary to conduct a lot of genetic testing with mice and gain knowledge of each disease.
Since arthropathy (Heberden tuberculosis), rheumatism, and collagen disease are genetic diseases, it is better to treat them as genetic diseases and to perform regenerative treatment for them.
何らかの原因(免疫機能不全)で欠損したすり減った軟骨部分が再生治療によって再生されると思います。I think that the worn cartilage part that is lost for some reason (immune dysfunction) will be regenerated by regenerative treatment.
整形外科分野のレベルを上げる事と、遺伝病対策としての遺伝子研究の充実を計る事です。
厚生省の遺伝病に対しての見直しが必要と思われます。To raise the level of orthopedics and to improve genetic research as a measure against genetic diseases.
The Ministry of Health and Welfare needs to review genetic diseases.
遺伝病という認識不足の為、実施例はありません。There is no working example due to lack of recognition of genetic disease.
ヒトゲノムプロジェクトを実施することにより、産業上にも大きな利益をもたらす事と思っております。We believe that implementing the Human Genome Project will bring significant benefits to the industry.
A アデニン
T チミン
G グアニン
C シトニンA Adenine T Thymine G Guanine C Cytonin
Claims (1)
遺伝子治療での再産医療であります。
がんと同様に関節症・リウマチ・膠原病数縁疾患は主に免疫機能の低下によるもだと思います。
整形外科の分野では実施応用化はされておりませんが、一種のホルモンであるエリスロポエチンの注射を患者に、細胞・再生した組織を自家移植して細胞培養による、組織再生、体性乾細胞による組織再生、胚性乾細胞(ES細胞)による組織再生、つまり、細胞組織あるいは、再生も働く生理活性物質や遺伝子を局所注射などで投与する事です。
要するに、関節症・リウマチ・膠原病数縁疾患者には、すり減った軟骨部分の再生も可能であると思います。It is reproductive medicine by gene therapy for regenerative treatment with arthropathy (Heberden tuberculosis) rheumatism / collagen disease related diseases.
Like cancer, arthropathy, rheumatism, and collagen disease are thought to be mainly due to a decline in immune function.
Although it has not been applied in practice in the field of orthopedics, erythropoietin, a kind of hormone, is injected into a patient, and cells and regenerated tissue are transplanted by self-transplantation by cell culture, tissue regeneration, tissue by somatic dry cells Regeneration, tissue regeneration by embryonic dry cells (ES cells), that is, administration of cell tissues or physiologically active substances and genes that also work by local injection.
In short, I think that it is possible to regenerate the worn cartilage part for people with arthropathy, rheumatism, and collagen disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007159514A JP2008279238A (en) | 2007-05-10 | 2007-05-10 | Regeneration treatment of arthropathy (heberden's nodositas), rheumatism, severe collagenosis marginal disease patient by gene therapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007159514A JP2008279238A (en) | 2007-05-10 | 2007-05-10 | Regeneration treatment of arthropathy (heberden's nodositas), rheumatism, severe collagenosis marginal disease patient by gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2008279238A true JP2008279238A (en) | 2008-11-20 |
Family
ID=40140548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007159514A Pending JP2008279238A (en) | 2007-05-10 | 2007-05-10 | Regeneration treatment of arthropathy (heberden's nodositas), rheumatism, severe collagenosis marginal disease patient by gene therapy |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2008279238A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006346420A (en) * | 2005-06-13 | 2006-12-28 | Univ Nagoya | Grafting material and bone improver |
-
2007
- 2007-05-10 JP JP2007159514A patent/JP2008279238A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006346420A (en) * | 2005-06-13 | 2006-12-28 | Univ Nagoya | Grafting material and bone improver |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230015146A1 (en) | Nucleic acid products and methods of administration thereof | |
JP2022000470A (en) | Nucleic acid products and methods of administration thereof | |
EP3684422B1 (en) | Connexin-43 gene therapy to restore electrical and cardiac function, and cardiac structure, in arrhythmogenic right ventricular cardiomyopathy | |
CN104650210B (en) | Preparation method as the TAT HOXB4H recombinant proteins of hematopoiesis irritant | |
ES2673861T3 (en) | Novel method to treat spinal cord damage using the hmgb1 fragment | |
Jakeman et al. | Injured mice at the gym: review, results and considerations for combining chondroitinase and locomotor exercise to enhance recovery after spinal cord injury | |
Delarue et al. | Inhibition of ADAMTS-4 expression in olfactory ensheathing cells enhances recovery after transplantation within spinal cord injury | |
JP2008279238A (en) | Regeneration treatment of arthropathy (heberden's nodositas), rheumatism, severe collagenosis marginal disease patient by gene therapy | |
Mammen et al. | Principles of gene therapy | |
Makarevich et al. | 657. Delivery of Genetically Engineered Adipose-Derived Cell Sheets for Treatment of Ischemic Disorders–Development of Application in Animal Models | |
Howell et al. | Spinal muscular atrophy: Huge steps | |
CN102895671B (en) | Application of microRNA to prevention and / or treatment of heart disease | |
KR101893339B1 (en) | Composition comprising GDF11 and uses thereof | |
Shroff | 660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy | |
Yan et al. | CircMap4k2 reactivated by aneurysm plication alleviates residual cardiac remodeling after SVR by enhancing cardiomyocyte proliferation in post-MI mice | |
TWI625392B (en) | Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases | |
CN108295249A (en) | Applications of the Sirt1 in the drug for preparing treatment treating myocardial ischemia damage | |
RU2817892C1 (en) | Personalized method of bone marrow restitution for controlling progression and recurrences of various civilization diseases, preventing aging and sudden death | |
Lux et al. | 658. Increasing Fetal Hemoglobin Expression With TALEN Induced Small Deletions in Peripheral Blood Stem Cells | |
Connelly et al. | 659. Precision Genome Engineering in Human Induced Pluripotent Stem Cells Using CRISPR/CAS9 | |
Xu et al. | Phospholipid-Coated Carbon Nanotubes as Neuromodulators to Protect against Ventricular Arrhythmias | |
Jianming | List of research projects available for prospective graduate students | |
JPWO2021214443A5 (en) | ||
Harper et al. | 129. Vector and Cell Mediated BMPR2 Therapy Ameliorates PAH | |
Mehta et al. | Migalastat HCI reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100713 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101130 |